About this trial
This study aims to develop a risk prediction model for patients who have undergone coronary revascularization (such as stent placement or bypass surgery). After these procedures, some patients still experience heart-related problems like chest pain, heart attack, or rehospitalization. This study will enroll 600 patients from multiple hospitals in China and follow them for 12 months. At enrollment and at 12, 24, 36, and 48 weeks after surgery, researchers will collect clinical information (including traditional Chinese medicine symptoms, blood tests, heart imaging) and biological samples (blood and tongue coating). Using artificial intelligence, the study will build a predictive model that combines Western medical data with traditional Chinese medicine characteristics. The goal is to better identify patients at higher risk of future heart events, so that personalized prevention and management can be provided. The study does not involve any experimental treatment or intervention - it is purely observational.
Eligibility criteria
Qualifiers
Diagnosis of coronary artery disease with prior coronary revascularization (PCI or CABG)
Age ≥ 18 years
Signed informed consent
Disqualifiers
Malignant arrhythmias, severe heart failure, myocardial disease, or structural heart disease
Severe pulmonary insufficiency, severe liver or kidney dysfunction, severe electrolyte disturbances
Pregnancy or breastfeeding
Severe psychiatric disorders, malignant tumors, hematologic diseases, rheumatic immune diseases, or severe infection
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Locations
Sponsors and collaborators
Liu Qiang
Lead sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Sponsor institution